116 compounds · evidence graded A to F · prices per mg from in-stock offers
peptide and research product database
Search 116 research product identities by name, alias, market and form. Read source-reviewed notes and compare dated vendor packages.
research market · not for human use
These vendors sell compounds as research chemicals. Most are not FDA-approved.
| compound | evidence | US status | from | lowest $/mg | median $/mg | vendors | assays per lot |
|---|---|---|---|---|---|---|---|
| Retatrutide GIP/GLP-1/glucagon triple agonist | investigational | $229.99 | $6.25 | $8.50 | 3 | 8× | |
| Cagrilintide long-acting amylin analogue | investigational | $99.99 | $10.00 | $10.80 | 3 | 8× | |
| Sermorelin GHRH 1–29 analogue | discontinued | $49.99 | $6.67 | $10.00 | 5 | 10× | |
| Thymosin Alpha-1 thymic peptide | compounding restricted | $59.99 | $6.00 | $12.25 | 4 | 8× | |
| SS-31 elamipretide | FDA-approved | $49.99 | $3.00 | $5.00 | 2 | 8× | |
| Mazdutide glucagon/GLP-1 dual agonist | investigational | — | — | — | — | — | |
| Survodutide glucagon/GLP-1 dual agonist | investigational | — | — | — | — | 4× |
7 of 116 compounds. Prices are listed prices before codes and shipping; per mg uses the package’s labelled amount. Evidence grades describe published human evidence, not product quality.
how the grades work
evidence grades
- approved, strong human outcome data
- phase 2–3 human trials, not yet approved
- small or early human studies
- animal or cell studies only
- contradicted, unsafe, or identity problems
Graded on published human evidence by an editorial first pass that is awaiting expert review. Grades come from the literature; no vendor can pay for a grade or a ranking. editorial policy